目的 探究疏風(fēng)解毒膠囊聯(lián)合丹參川芎嗪注射液治療慢性阻塞性肺疾病急性加重期（AECOPD）的臨床療效。方法 選取2015年1月—2016年6月在上海市浦東新區(qū)康橋社區(qū)衛(wèi)生服務(wù)中心接受治療的老年AECOPD患者98例為研究對(duì)象，隨機(jī)分為對(duì)照組和治療組，每組各49例。對(duì)照組患者靜脈滴注丹參川芎嗪注射液，10 mL/次，1次/d。治療組患者在對(duì)照組的基礎(chǔ)上口服疏風(fēng)解毒膠囊，10粒/次，3次/d。兩組患者均持續(xù)治療2周。評(píng)價(jià)治療后兩組患者臨床療效，同時(shí)比較治療前后兩組患者肺功能、血?dú)夤δ?、白?xì)胞介素-8（IL-8）和腫瘤壞死因子-α（TNF-α）水平以及臨床癥狀改善情況。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為79.6%、95.9%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。治療后，兩組患者一秒用力呼氣容積（FEV₁）、用力肺活量（FVC）和FEV₁/FVC指標(biāo)均明顯提高（P< 0.05）；且治療組患者上述肺功能指標(biāo)明顯優(yōu)于對(duì)照組（P< 0.05）。治療后，兩組患者二氧化碳分壓（pCO₂）、IL-8和TNF-α水平均顯著降低，氧分壓（pO₂）、血氧飽和度（SaO₂）均明顯升高，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）；且治療組上述指標(biāo)改善情況明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。治療后，兩組呼吸困難評(píng)分均明顯降低，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）；治療后，治療組患者呼吸困難評(píng)分明顯低于對(duì)照組，且咳痰、咳嗽、喘息、胸悶等臨床癥狀的改善例數(shù)明顯多于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。結(jié)論 疏風(fēng)解毒膠囊聯(lián)合丹參川芎嗪注射液能夠明顯提高AECOPD患者的肺功能、血?dú)夤δ懿⒏纳婆R床癥狀，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the clinical effect of Shufeng Jiedu Capsules combined with Salviae Miltiorrhizae and Ligustrazine Hydrochloride Injection in treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods Patients (98 cases) with AECOPD in Kangqiao Community Health Service Center of Pudong New District in Shanghai from January 2015 to June 2016 were randomly divided into control and treatment groups, and each group had 49 cases. Patients in the control group were iv administered with Salviae Miltiorrhizae and Ligustrazine Hydrochloride Injection, 10 mL/time, once daily. Patients in the treatment group were po administered with Shufeng Jiedu Capsules on the basis of the control group, 10 grains/time, three times daily. Patients in two groups were treated for two weeks. After treatment, clinical efficacy was evaluated, and lung function, blood gas function, IL-8 and TNF-α levels, and the improvement of clinical symptoms in two groups before and after treatment were compared.Results After treatment, the clinical efficacy in the control and treatment groups were 79.6% and 95.9%, respectively, and there were differences between two groups (P < 0.05). After treatment, the FEV₁, FVC and FEV₁/FVC indexes in two groups were significantly increased(P < 0.05). And the lung function indexes in the treatment group were significantly better than those in the control group (P < 0.05). After treatment, the pCO₂, IL-8 and TNF-α levels in two groups were significantly decreased, pO₂ and SaO₂ were significantly increased, and there were differences in the same group (P < 0.05). And the improvement of these indicators in the treatment group was significantly better than that in the control group, with significant difference between two groups (P < 0.05). After treatment, the dyspnea scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the dyspnea scores in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the patients of improved clinical symptoms of expectoration, coughing, wheezing, chest tightness in the treatment group was significantly more than patients in the control group, with significant difference between two groups (P < 0.05). Conclusion Shufeng Jiedu Capsules combined with Salviae Miltiorrhizae and Ligustrazine Hydrochloride Injection can significantly improve lung function, blood gas function, and clinical symptoms of AECOPD patients, which has a certain clinical application value.

上海市浦東新區(qū)衛(wèi)生系統(tǒng)優(yōu)秀社區(qū)適宜人才培養(yǎng)項(xiàng)目（PWRs2014-07）